Ipriflavone
Chemical compound / From Wikipedia, the free encyclopedia
Ipriflavone (INN, JAN; brand name Yambolap) is a synthetic isoflavone which may be used to inhibit bone resorption,[2] maintain bone density and to prevent osteoporosis in postmenopausal women.[1] It is not used to treat osteoporosis. It slows down the action of the osteoclasts (bone-eroding cells), possibly allowing the osteoblasts (bone-building cells) to build up bone mass.
Clinical data | |
---|---|
Trade names | Yambolap |
Other names | FLI13; 7-Isopropoxyisoflavone[1] |
AHFS/Drugs.com | International Drug Names |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.125.854 |
Chemical and physical data | |
Formula | C18H16O3 |
Molar mass | 280.323 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
A clinical trial reported in 2001 that it was not effective in prevention or treatment of osteoporosis.[3]
A double-blind study reveals that ipriflavone might be effective on reducing tinnitus on otosclerosis sufferers.[4]
Ipriflavone has been described as a phytoestrogen.[5] However, this is incorrect, as the drug does not bind to or activate the estrogen receptor and shows no estrogenic effects in postmenopausal women.[6][7] The drug prevents bone loss via mechanisms that are distinct from those of estrogens.[5]
- Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 651–. ISBN 978-1-4757-2085-3.
- Alexandersen P, Toussaint A, Christiansen C, Devogelaer JP, Roux C, Fechtenbaum J, et al. (Ipriflavone Multicenter European Fracture Study) (March 2001). "Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial". JAMA. 285 (11): 1482–8. doi:10.1001/jama.285.11.1482. PMID 11255425.
- Ipriflavone at PDR Health